golimumab (Simponi)

following a re-submission

golimumab (Simponi®) is accepted for restricted use within NHS Scotland.

Indication under review: Alone or in combination with methotrexate, for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

SMC restriction: golimumab is restricted to use in patients whose disease has not responded to adequate trials of at least two standard DMARDs, administered either individually or in combination. It is also restricted to use at a dose of 50mg only.

Golimumab has demonstrated efficacy when compared with placebo in patients with active psoriatic arthritis who have had an inadequate response to DMARDs or non-steroidal anti-inflammatory drugs (NSAIDs).

The economic case was demonstrated for golimumab when used at a dose of 50mg.  The economic case was not demonstrated for the 100mg dose of golimumab.